Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Inclusion Criteria: * Age \> 18 years of age * Symptomatic VMA, VMT, or macular hole * BCVA 20/30 - CF 3' Snellen equivalent * Willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments * JETREA® treatment naïve Exclusion Criteria: * Patients who are pregnant, planning to become pregnant, or breastfeeding a child * Uncontrolled ocular hypertension or glaucoma in study (defined as IOP ≥ 25mm Hg or a cup to disc ratio (CDR) \> 0.8 despite treatment with anti-glaucoma medication) * Active malignancies within the last 12 months except appropriately treated carcinoma in situ of the crevices, melanoma, and prostate cancers treated with a curative intent * Inability to comply with study or follow-up procedures * Women who may become pregnant or lactating or intend to become pregnant during the study * Known drug allergy to ocriplasmin or eplerenone * Patients with known contraindications Eplerenone as outlined in the package insert